Reyes Financial Architecture Inc. Purchases 132 Shares of Amgen Inc. $AMGN

by · The Markets Daily

Reyes Financial Architecture Inc. boosted its position in shares of Amgen Inc. (NASDAQ:AMGN – Free Report) by 15.7% in the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 972 shares of the medical research company’s stock after purchasing an additional 132 shares during the period. Reyes Financial Architecture Inc.’s holdings in Amgen were worth $271,000 at the end of the most recent quarter.

Other institutional investors also recently modified their holdings of the company. Wealth Preservation Advisors LLC bought a new position in shares of Amgen in the first quarter worth about $25,000. First Pacific Financial raised its stake in shares of Amgen by 304.5% in the first quarter. First Pacific Financial now owns 89 shares of the medical research company’s stock worth $28,000 after acquiring an additional 67 shares during the last quarter. CBIZ Investment Advisory Services LLC raised its stake in shares of Amgen by 1,214.3% in the first quarter. CBIZ Investment Advisory Services LLC now owns 92 shares of the medical research company’s stock worth $29,000 after acquiring an additional 85 shares during the last quarter. Pinney & Scofield Inc. bought a new position in shares of Amgen in the fourth quarter worth about $26,000. Finally, Activest Wealth Management raised its stake in shares of Amgen by 3,433.3% in the first quarter. Activest Wealth Management now owns 106 shares of the medical research company’s stock worth $33,000 after acquiring an additional 103 shares during the last quarter. 76.50% of the stock is owned by institutional investors.

Analysts Set New Price Targets

AMGN has been the subject of a number of research analyst reports. Citigroup boosted their target price on shares of Amgen from $305.00 to $310.00 and gave the stock a “neutral” rating in a research note on Wednesday, August 6th. Piper Sandler boosted their price target on shares of Amgen from $328.00 to $342.00 and gave the stock an “overweight” rating in a research note on Monday, August 25th. Guggenheim assumed coverage on shares of Amgen in a research note on Tuesday, May 20th. They set a “neutral” rating and a $288.00 price target for the company. William Blair reissued an “outperform” rating on shares of Amgen in a research note on Tuesday, June 24th. Finally, Bank of America boosted their price target on shares of Amgen from $252.00 to $261.00 and gave the stock an “underperform” rating in a research note on Wednesday, July 23rd. Seven research analysts have rated the stock with a Buy rating, twelve have assigned a Hold rating and two have given a Sell rating to the company. According to MarketBeat.com, the company presently has an average rating of “Hold” and an average target price of $304.43.

Get Our Latest Stock Report on Amgen

Insider Transactions at Amgen

In related news, SVP Nancy A. Grygiel sold 1,267 shares of the business’s stock in a transaction that occurred on Wednesday, August 20th. The shares were sold at an average price of $296.99, for a total transaction of $376,286.33. Following the completion of the transaction, the senior vice president owned 7,209 shares in the company, valued at approximately $2,141,000.91. The trade was a 14.95% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Corporate insiders own 0.69% of the company’s stock.

Amgen Stock Down 0.7%

Shares of NASDAQ AMGN opened at $274.40 on Tuesday. The stock has a market cap of $147.73 billion, a P/E ratio of 22.44, a P/E/G ratio of 2.40 and a beta of 0.49. The firm has a 50 day moving average price of $292.17 and a 200 day moving average price of $291.33. The company has a debt-to-equity ratio of 7.24, a quick ratio of 0.98 and a current ratio of 1.31. Amgen Inc. has a 52-week low of $253.30 and a 52-week high of $339.17.

Amgen (NASDAQ:AMGN – Get Free Report) last issued its quarterly earnings data on Tuesday, August 5th. The medical research company reported $6.02 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $5.28 by $0.74. The firm had revenue of $9.18 billion during the quarter, compared to analysts’ expectations of $8.86 billion. Amgen had a net margin of 18.96% and a return on equity of 174.71%. The business’s revenue for the quarter was up 9.4% on a year-over-year basis. During the same quarter in the previous year, the company earned $4.97 earnings per share. Amgen has set its FY 2025 guidance at 20.200-21.300 EPS. Analysts expect that Amgen Inc. will post 20.62 EPS for the current year.

Amgen Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Friday, September 12th. Investors of record on Friday, August 22nd were issued a dividend of $2.38 per share. The ex-dividend date was Friday, August 22nd. This represents a $9.52 dividend on an annualized basis and a yield of 3.5%. Amgen’s payout ratio is currently 77.84%.

About Amgen

(Free Report)

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.

Featured Articles

Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen Inc. (NASDAQ:AMGN – Free Report).